CRISPR Therapeutics AG (CRSP) Non-Current Assets (2015 - 2026)

CRISPR Therapeutics AG has disclosed Non-Current Assets across 12 years of filings, most recently posting $279.0 million for Q2 2026.

• In Q2 2026, Non-Current Assets fell 5.76% year-over-year to $279.0 million; the TTM figure through Jun 2026 stood at $1.2 billion (down 4.9% YoY), while the FY2025 annual figure was $279.6 million, down 8.31% from the prior year.
• Non-Current Assets came in at $279.0 million for Q2 2026 at CRISPR Therapeutics AG, up from $277.5 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $420.7 million in Q3 2022 to a low of $277.5 million in Q1 2026.
• Average Non-Current Assets over 5 years is $324.8 million, with a median of $320.4 million recorded in 2023.
• Year-over-year, Non-Current Assets jumped 175.23% in 2022 and fell 22.44% in 2023.
• Over 5 years, Non-Current Assets stood at $390.0 million in 2022, then decreased by 17.57% to $321.5 million in 2023, then retreated by 5.16% to $304.9 million in 2024, then dropped by 8.31% to $279.6 million in 2025, then retreated by 0.2% to $279.0 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $279.0 million in Q2 2026, $277.5 million in Q1 2026, and $279.6 million in Q4 2025.